By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Quinolones and fluoroquinolones > Cipro > Cipro Dosage
Quinolones and fluoroquinolones
https://themeditary.com/dosage-information/cipro-dosage-215.html

Cipro Dosage

Drug Detail:Cipro (Ciprofloxacin (oral) [ sip-roe-flox-a-sin ])

Generic Name: CIPROFLOXACIN HYDROCHLORIDE 250mg

Dosage Form: tablet, film coated

Drug Class: Quinolones and fluoroquinolones

Contents
Uses Warnings Before Taking Dosage Side effects Interactions FAQ

CIPRO Tablets and Oral Suspension should be administered orally as described in the appropriate Dosage Guidelines tables.

Dosage in Adults

The determination of dosage and duration for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient’s host-defense mechanisms, and the status of renal and hepatic function. CIPRO Tablets or Oral Suspension may be administered to adult patients when clinically indicated at the discretion of the physician. Administer CIPRO for Oral Suspension using the co-packaged graduated spoon [see Dosage and Administration (2.7)].

Table 1: Adult Dosage Guidelines
*
Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms of infection have disappeared, except for inhalational anthrax (post-exposure).
†
Used in conjunction with metronidazole.
‡
Begin drug administration as soon as possible after suspected or confirmed exposure.
Infection
Dose
Frequency
Usual Durations*
Skin and Skin Structure
500–750 mg
every 12 hours
7 to 14 days
Bone and Joint
500–750 mg
every 12 hours
4 to 8 weeks
Complicated Intra–Abdominal†
500 mg
every 12 hours
7 to 14 days
Infectious Diarrhea
500 mg
every 12 hours
5 to 7 days
Typhoid Fever
500 mg
every 12 hours
10 days
Uncomplicated Urethral and Cervical Gonococcal Infections
250 mg
single dose
single dose
Inhalational anthrax (post-exposure)‡
500 mg
every 12 hours
60 days
Plague‡
500–750 mg
every 12 hours
14 days
Chronic Bacterial Prostatitis
500 mg
every 12 hours
28 days
Lower Respiratory Tract Infections
500–750 mg
every 12 hours
7 to 14 days
Urinary Tract Infections
250–500 mg
every 12 hours
7 to 14 days
Acute Uncomplicated Cystitis
250 mg
every 12 hours
3 days
Acute Sinusitis
500 mg
every 12 hours
10 days

Conversion of IV to Oral Dosing in Adults

Patients whose therapy is started with CIPRO IV may be switched to CIPRO Tablets or Oral Suspension when clinically indicated at the discretion of the physician (Table 2) [see Clinical Pharmacology (12.3)].

Table 2: Equivalent AUC Dosing Regimens

CIPRO Oral Dosage

Equivalent CIPRO IV Dosage

250 mg Tablet every 12 hours

200 mg intravenous every 12 hours

500 mg Tablet every 12 hours

400 mg intravenous every 12 hours

750 mg Tablet every 12 hours

400 mg intravenous every 8 hours

Dosage in Pediatric Patients

Dosing and initial route of therapy (that is, IV or oral) for cUTI or pyelonephritis should be determined by the severity of the infection. CIPRO should be administered as described in Table 3. Administer CIPRO for Oral Suspension using the co-packaged graduated spoon [see Dosage and Administration (2.7)].

Table 3: Pediatric Dosage Guidelines
Infection Dose Frequency Total Duration

Complicated Urinary Tract or Pyelonephritis

(patients from 1 to 17 years of age)

10 mg/kg to 20 mg/kg

(maximum 750 mg per dose; not to be exceeded even in patients weighing more than 51 kg)

Every 12 hours

10–21 days

Inhalational Anthrax (Post-Exposure)2

15 mg/kg

(maximum 500 mg per dose)

Every 12 hours

60 days

Plague2,3

15 mg/kg

(maximum 500 mg per dose)

Every 8 to 12 hours

10–21 days

Dosage Modifications in Patients with Renal Impairment

Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction. Dosage guidelines for use in patients with renal impairment are shown in Table 4.

Table 4: Recommended Starting and Maintenance Doses for Adult Patients with Impaired Renal Function

Creatinine Clearance (mL/min)

Dose

> 50

See Usual Dosage.

30–50

250–500 mg every12 hours

5–29

250–500 mg every 18 hours

Patients on hemodialysis or Peritoneal dialysis

250–500 mg every 24 hours (after dialysis)

When only the serum creatinine concentration is known, the following formulas may be used to estimate creatinine clearance:

Men - Creatinine clearance (mL/min) = Weight (kg) x (140–age)

72 x serum creatinine (mg/dL)

Women - 0.85 x the value calculated for men.

The serum creatinine should represent a steady state of renal function.

In patients with severe infections and severe renal impairment, a unit dose of 750 mg may be administered at the intervals noted above. Patients should be carefully monitored.

Pediatric patients with moderate to severe renal insufficiency were excluded from the clinical trial of cUTI and pyelonephritis. No information is available on dosing adjustments necessary for pediatric patients with moderate to severe renal insufficiency (that is, creatinine clearance of < 50 mL/min/1.73m2).

Important Administration Instructions

With Multivalent Cations

Administer CIPRO at least 2 hours before or 6 hours after magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate) or sucralfate; Videx® (didanosine) chewable/buffered tablets or pediatric powder for oral solution; other highly buffered drugs; or other products containing calcium, iron or zinc.

With Dairy Products

Concomitant administration of CIPRO with dairy products (like milk or yogurt) or calcium-fortified juices alone should be avoided since decreased absorption is possible; however, CIPRO may be taken with a meal that contains these products.

Hydration of Patients Receiving CIPRO

Assure adequate hydration of patients receiving CIPRO to prevent the formation of highly concentrated urine. Crystalluria has been reported with quinolones.

Instruct the patient of the appropriate CIPRO administration [see Patient Counseling Information (17)].

Directions for Reconstitution of the CIPRO Microcapsules for Oral Suspension

CIPRO Oral Suspension is supplied in 5% (5 g ciprofloxacin in 100 mL) and 10% (10 g ciprofloxacin in 100 mL) strengths. CIPRO oral suspension is composed of two components (microcapsules and diluent) that must be combined prior to dispensing.

Table 5: Appropriate Dosing Volumes of the Reconstituted Oral Suspensions

Dose

5%

(250 mg/5 mL)

10%

(500 mg/5 mL)

250 mg

5 mL

2.5 mL

500 mg

10 mL

5 mL

750 mg

15 mL

7.5 mL

Preparation of the suspension:

Step1

Step 1

The small bottle contains the microcapsules, the large bottle contains the diluent.

Step 2

Step 2

Open both bottles. Child-proof cap: Press down according to instructions on the cap while turning to the left.

Step 3

Step 3

Pour the microcapsules completely into the larger bottle of diluent. Do not add water to the suspension.

Step 4

Step 4
1.
Remove the top layer of the diluent bottle label (to reveal the CIPRO Oral Suspension label). Close the large bottle completely according to the directions on the cap and shake vigorously for about 15 seconds. The suspension is ready for use.

Step 5: Write the expiration date of the re-constituted oral suspension on the bottle label.

Reconstituted product may be stored below 30°C (86°F) for 14 days. Protect from freezing.

No additions should be made to the mixed final ciprofloxacin suspension. CIPRO Oral Suspension should not be administered through feeding or NG (nasogastric) tubes due to its physical characteristics.

Administration Instructions for CIPRO for Oral Suspension After Reconstitution

•
Shake CIPRO Oral Suspension vigorously each time before use for approximately 15 seconds.
•
Administer CIPRO Oral Suspension using the co-packaged graduated teaspoon provided for the patient (see Figure 1)
gradated spoon

Figure 1: Co-packaged 5 mL graduated teaspoon

The Co-packaged graduated teaspoon (5mL) is provided, with markings for 1/2 (2.5 mL) and 1/1 (5 mL)

•
After use, clean the graduated teaspoon under running water with dish detergent and dry thoroughly.
•
Do Not chew the microcapsules in the CIPRO Oral Suspension, instead swallow them whole.
•
Water may be taken afterwards.
•
Reclose the bottle properly after each use according to instructions on the cap.

After treatment has been completed, CIPRO Oral Suspension should not be reused.

Dosing of CIPRO for Oral Suspension using the Co-Packaged Spoon in Adults and Pediatric Patients

Table : 5% Cipro for Oral Suspension: 250 mg ciprofloxacin per 5 mL after reconstitution

Infection

Body weight (kg)

Dose by Measuring Spoonful(s) using Co-Packed Spoon*
(teaspoonful (s) (volume (mL))

Dose Strength

(mg)

Complicated Urinary Tract or Pyelonephritis (patients from 1 to 17 years of age)1

and Plague2

9 kg to 12 kg

½ teaspoonful (2.5 mL)

125 mg

13 kg to 18 kg

1 teaspoonful (5 mL)

250 mg

19 kg to 24 kg

1 to 1 ½ teaspoonful(s) (5 mL to 7.5 mL)

250 mg̶̶ to 375 mg

25 kg to 31 kg

1 ½ to 2 teaspoonfuls (7.5 mL to 10 mL)

375 mg to 500 mg

32 kg to 37 kg

1 ½ to 2 ½ teaspoonfuls (7.5 mL to 12.5 mL)

375 mg to 625 mg

38 kg or more

2 to 3 teaspoonfuls (10 mL to 15 mL)

500 mg to 750 mg

Inhalational Anthrax (Post-Exposure)3

9 kg to 12 kg

½ teaspoonful (2.5 mL)

125 mg

13 kg to 18 kg

1 teaspoonful (5 mL)

250 mg

19 kg to 24 kg

1 to 1 ½ teaspoonful(s) (5 mL to 7.5 mL)

250 mg̶̶ to 375 mg

25 kg or more

2 teaspoonfuls (10 mL)

500 mg

* A graduated teaspoon (5mL) with markings 1/2 (2.5) mL and 1/1 (5 mL) is provided for the patient.

1Administer every 12 hours for 10-21 days [see Dosage and Administration (2.2)]

2Administer every 8-12 hours for 10-21 days for Pediatric patients [see Dosage and Administration (2.2)]; for adults administer every 12 hours for 14 days [see Dosage and Administration (2.1)]

3Administer every 12 hours for 60 days [see Dosage and Administration (2.1 and 2.2)]

Table 7: 10% Oral Suspension: 500 mg ciprofloxacin per 5 mL after reconstitution (not appropriate for children weighing less than 13 kg)

Infection

Body weight (kg)

Dose by Measuring Spoonful(s) using Co-Packed Spoon* (teaspoonful (s) (volume (mL))

Dose Strength

(mg)

Complicated Urinary Tract or Pyelonephritis (patients from 1 to 17 years of age)1

and Plague2

13 kg to 24 kg

½ teaspoonful (2.5 mL)

250 mg

25 kg

½ to 1 teaspoonful (2.5 mL to 5 mL)

250 mg to 500 mg

26 kg to 37 kg

1 teaspoonful (5 mL)

500 mg

38 kg or more

1 to 1½ teaspoonful(s) (5 mL to 7.5 mL)

500 mg to maximum dose of 750 mg

Inhalational Anthrax (Post-Exposure)3

13 kg to 24 kg

½ teaspoonful (2.5 mL)

250 mg

25 kg or more

1 teaspoonful (5 mL)

500 mg

* A graduated teaspoon (5mL) with markings 1/2 (2.5) mL and 1/1 (5 mL) is provided for the patient.

1Administer every 12 hours for 10-21 days [see Dosage and Administration (2.2)]

2Administer every 8-12 hours for 10-21 days for Pediatric patients [see Dosage and Administration (2.2)]; for adults administer every 12 hours for 14 days [see Dosage and Administration (2.1)]

3Administer every 12 hours for 60 days [see Dosage and Administration (2.1 and 2.2)]

Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by